FDA Sends Proposed Interim Peptide Access Policy to White House for Review
The U.S. Food and Drug Administration (FDA) has submitted a proposed interim access policy for peptides to the White House for review, a move that could allow compounding pharmacies to temporarily produce and distribute previously restricted peptide products.
Sioux Falls, SD, October 15, 2026 —
The U.S. Food and Drug Administration has sent a proposed interim access policy for peptides to the White House for review. If adopted, the policy could allow compounding pharmacies to temporarily produce and distribute peptide products that were previously restricted.
The submission marks a review stage for the proposal, not confirmation that the policy has taken effect. The summary provided does not state when the White House review began, how long it may take or when a decision could be made. It also does not describe the terms of the proposed policy.
Details about which peptide products could be covered were not provided. The available information also does not identify the reason those products were restricted, specify how long any temporary access period might last or explain what conditions pharmacies would have to meet.
The potential change described is limited to the possibility of temporary production and distribution by compounding pharmacies. The proposal’s submission does not establish that pharmacies are currently permitted to make or distribute the products, or that the White House has approved the policy.
The FDA’s proposed policy remains under review, based on the information available. No further details about the review, the policy’s scope or its possible implementation were included in the summary.
Story summarized from the original created by Nathaniel Weixel,Joseph Choi on thehill.com, see more information here.
Media gallery
